Skip to main
DYN
DYN logo

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics Inc. is demonstrating significant progress in its clinical-stage pipeline, particularly with DYNE-251 and DYNE-101, which have shown meaningful improvements in dystrophin expression levels and functional outcomes in patients with neuromuscular diseases. The clinical data indicates favorable safety profiles alongside encouraging efficacy metrics, which may position these therapeutics favorably for potential accelerated approval, especially with DYNE-251's promising data suggesting high probability of success in upcoming expansion cohorts. The advancements in their FORCE platform further bolster Dyne Therapeutics' outlook by addressing critical limitations in drug delivery to muscle tissue and the central nervous system, supporting a strong foundation for future growth and development.

Bears say

Dyne Therapeutics faces significant challenges in clinical development, particularly with the DYNE-251 program, where data suggests diminishing efficacy over time, with splicing improvement notably dropping from 25% at three months to only 3% at six months. This decline raises concerns about the therapy's overall efficacy and safety profile, which could notably hinder the stock performance. Additionally, potential payer headwinds related to reimbursement for DYNE-251 may further negatively impact financial forecasts and investor confidence in Dyne Therapeutics's prospects.

Dyne Therapeutics (DYN) has been analyzed by 26 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 26 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.